高剂量卡铂治疗后的肾功能障碍。
Renal dysfunction following high-dose carboplatin treatment.
作者信息
Mulder P O, Sleijfer D T, de Vries E G, Uges D R, Mulder N H
机构信息
Department of Intensive care Medicine, University Hospital, Groningen, The Netherlands.
出版信息
J Cancer Res Clin Oncol. 1988;114(2):212-4. doi: 10.1007/BF00417840.
Abstract
A case history is reported or renal failure during and after treatment with carboplatin for 3 days, total dose 750 mg/m2, in a conditioning regimen prior to autologous bone marrow transplantation. Pretreatment renal function was compromised after nephrectomy and chemotherapy with cisplatin. A decrease in glomerular filtration rate concurred with a decrease in excretion of platinum in the urine and an increase in urinary beta 2 microglobulin. Treatment with high-dose carboplatin in patients with impaired renal function and previous treatment with cisplatin may lead to further loss of renal function.
摘要
报告了1例在自体骨髓移植前的预处理方案中，接受卡铂治疗3天、总剂量750mg/m²期间及之后出现肾衰竭的病例。肾切除术后和顺铂化疗后，患者预处理时的肾功能已受损。肾小球滤过率下降的同时，尿铂排泄减少，尿β2微球蛋白增加。肾功能受损且既往接受过顺铂治疗的患者，使用大剂量卡铂治疗可能导致肾功能进一步丧失。
相似文献
1
Renal dysfunction following high-dose carboplatin treatment.高剂量卡铂治疗后的肾功能障碍。
J Cancer Res Clin Oncol. 1988;114(2):212-4. doi: 10.1007/BF00417840.
2
Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.儿童癌症潜在肾毒性治疗后的早期和晚期肾脏不良反应。
Cochrane Database Syst Rev. 2013 Oct 8(10):CD008944. doi: 10.1002/14651858.CD008944.pub2.
3
Investigations on the acute and chronic nephrotoxicity of the new platinum analogue carboplatin.新型铂类类似物卡铂的急性和慢性肾毒性研究。
J Cancer Res Clin Oncol. 1990;116(2):203-6. doi: 10.1007/BF01612678.
4
Different infusion durations for preventing platinum-induced hearing loss in children with cancer.预防癌症患儿铂类药物所致听力损失的不同输注持续时间
Cochrane Database Syst Rev. 2016 Aug 8(8):CD010885. doi: 10.1002/14651858.CD010885.pub3.
5
Platinum-induced hearing loss after treatment for childhood cancer.儿童癌症治疗后铂诱导的听力损失。
Cochrane Database Syst Rev. 2016 Aug 3;2016(8):CD010181. doi: 10.1002/14651858.CD010181.pub2.
6
Platinum-containing regimens for metastatic breast cancer.转移性乳腺癌的含铂方案。
Cochrane Database Syst Rev. 2017 Jun 23;6(6):CD003374. doi: 10.1002/14651858.CD003374.pub4.
7
Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study.以自体骨髓为支持，递增剂量卡铂联合大剂量异环磷酰胺：一项I期研究。
J Cancer Res Clin Oncol. 1991;117 Suppl 4(Suppl 4):S208-13. doi: 10.1007/BF01613229.
8
Different infusion durations for preventing platinum-induced hearing loss in children with cancer.预防癌症患儿铂类药物所致听力损失的不同输注持续时间
Cochrane Database Syst Rev. 2018 Jul 5;7(7):CD010885. doi: 10.1002/14651858.CD010885.pub4.
9
A systematic overview of chemotherapy effects in ovarian cancer.卵巢癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):340-60. doi: 10.1080/02841860151116420.
10
Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.新诊断的II期、III期或IV期上皮性卵巢癌术后患者一线化疗的系统评价
Gynecol Oncol. 2002 Apr;85(1):71-80. doi: 10.1006/gyno.2001.6552.
引用本文的文献
1
Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer.卡铂。对其药效学、药代动力学特性及在癌症治疗中的疗效的初步综述。
Drugs. 1989 Feb;37(2):162-90. doi: 10.2165/00003495-198937020-00005.
2
Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.卡铂剂量为750mg/m²，连续三天给药的药代动力学。
Br J Cancer. 1990 Mar;61(3):460-4. doi: 10.1038/bjc.1990.101.
3
Investigations on the acute and chronic nephrotoxicity of the new platinum analogue carboplatin.新型铂类类似物卡铂的急性和慢性肾毒性研究。
J Cancer Res Clin Oncol. 1990;116(2):203-6. doi: 10.1007/BF01612678.
本文引用的文献
1
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.顺-二氨-1,1-环丁烷二羧酸铂II的早期临床研究。
Cancer Chemother Pharmacol. 1982;9(3):140-7. doi: 10.1007/BF00257742.
2
3
Phase I clinical and pharmacologic trial of carboplatin daily for 5 days.卡铂每日给药5天的I期临床和药理学试验。
Cancer Treat Rep. 1984 Sep;68(9):1103-14.
4
5
A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240).二胺环丁烷二羧酸铂（NSC 241240）的I期及药代动力学研究
Cancer Res. 1983 Sep;43(9):4470-3.
6
Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.新型铂类类似物JM8用于晚期卵巢癌的II期研究。
Cancer Treat Rep. 1983 Nov;67(11):997-1000.
7
Influence of platinum-induced renal toxicity on bleomycin-induced pulmonary toxicity in patients with disseminated testicular carcinoma.
Oncology. 1984;41(1):4-7. doi: 10.1159/000225781.
8
TNO-6-induced acute renal failure. A case report.TNO - 6诱导的急性肾衰竭。病例报告。
Cancer. 1985 Oct 1;56(7):1511-4. doi: 10.1002/1097-0142(19851001)56:7<1511::aid-cncr2820560706>3.0.co;2-l.
9
Preclinical antitumor and toxicologic profile of carboplatin.卡铂的临床前抗肿瘤和毒理学概况。
Cancer Treat Rev. 1985 Sep;12 Suppl A:1-19. doi: 10.1016/0305-7372(85)90014-3.
10
Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin.
J Clin Oncol. 1986 Sep;4(9):1392-8. doi: 10.1200/JCO.1986.4.9.1392.
Zotero 插件